1. In Vivo
  2. >>Global Vision

The Battle For OGS

 
• By Hazel Dawson

Celltech's hostile bid for OGS may have scuppered the company's cosy merger plans with CAT. But OGS isn't giving in without a fight. And Celltech's offer may even prove beneficial to OGS shareholders, bumping up the firm's price-tag for CAT--or another suitor.

When Oxford GlycoSciences PLC (OGS) in January 2003 announced its proposed merger with compatriot Cambridge Antibody Technology Group PLC (CAT), it became the first European biotech to agree to an offer that valued it at less than the cash on its balance sheet. (See "CAT Merges for Money: Chooses Well-Dowered OGS," In Vivo Europe Rx, February 2003 Also see "CAT Merges for Money; Chooses Well-Dowered OGS" - In Vivo, 1 February, 2003. [See Deal].)

CAT's £110 million ($178 million) offer, about £25 million below the level of cash on OGS' balance sheet (as disclosed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.